Int J Stem Cells.  2016 May;9(1):90-95. 10.15283/ijsc.2016.9.1.90.

Treatment of Cerebral Palsy with Stem Cells: A Report of 17 Cases

• Abi Chahine NH
• Wehbe TW
• Hilal RA
• Zoghbi VV
• Melki AE
• Bou Habib

• KMID: 2164165
• DOI: http://doi.org/10.15283/ijsc.2016.9.1.90

Abstract

Cerebral Palsy (CP) is a disabling condition that affects a child's life and his/her family irreversibly. It is usually a non-progressive condition but improvement over time is rarely seen. The condition can be due to prenatal hypoxia, metabolic, genetic, infectious, traumatic or other causes. It is therefore a heterogeneous group that results in functional motor disability associated with different degrees of cognitive abnormalities. There are no treatments that can cure or even improve CP and the best available approach aims at functional, social and nutritional supportive care and counseling. In this paper, we report 17 sequential patients with CP treated with intrathecal administration of Bone Marrow Mononuclear Cells (BMMC). All patients had an uneventful post-injection course with 73% of the evaluable patients treated having a good response using the Gross Motor Function Classification System (GMFCS). The average improvement was 1.3 levels on the GMFCS with cognitive improvements as well.

Keyword

Stem cells; Bone Marrow Mononuclear Cells; Cerebral palsy; Intrathecal injection

MeSH Terms

Anoxia
Bone Marrow
Cerebral Palsy*
Classification
Counseling
Humans
Injections, Spinal
Nutritional Support
Stem Cells*

Reference

References

1. Spencer NJ, Blackburn CM, Read JM. Disabling chronic conditions in childhood and socioeconomic disadvantage: a systematic review and meta-analyses of observational studies. BMJ Open. 2015; 5:e007062. DOI: 10.1136/bmjopen-2014-007062. PMID: 26338834. PMCID: 4563224.

2. My Child at CerebralPalsy.org [Internet]. 2015. Oct. Available from: http://cerebralpalsy.org/about-cerebral-palsy/costs/.

3. Andersen GL, Irgens LM, Haagaas I, Skranes JS, Meberg AE, Vik T. Cerebral palsy in Norway: prevalence, subtypes and severity. Eur J Paediatr Neurol. 2008; 12:4–13. DOI: 10.1016/j.ejpn.2007.05.001.

4. Cauraugh JH, Naik SK, Hsu WH, Coombes SA, Holt KG. Children with cerebral palsy: a systematic review and meta-analysis on gait and electrical stimulation. Clin Rehabil. 2010; 24:963–978. DOI: 10.1177/0269215510371431. PMID: 20685722.

5. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, Jacobsson B, Damiano D. Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005; 47:571–576. DOI: 10.1017/S001216220500112X. PMID: 16108461.

6. Driscoll SW, Skinner J. Musculoskeletal complications of neuromuscular disease in children. Phys Med Rehabil Clin N Am. 2008; 19:163–194. DOI: 10.1016/j.pmr.2007.10.003. PMID: 18194756.

7. Christensen D, Van Naarden Braun K, Doernberg NS, Maenner MJ, Arneson CL, Durkin MS, Benedict RE, Kirby RS, Wingate MS, Fitzgerald R, Yeargin-Allsopp M. Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning - Autism and Developmental Disabilities Monitoring Network, USA, 2008. Dev Med Child Neurol. 2014; 56:59–65. DOI: 10.1111/dmcn.12268.

8. Shevell MI, Dagenais L, Hall N. REPACQ CONSORTIUM. The relationship of cerebral palsy subtype and functional motor impairment: a population-based study. Dev Med Child Neurol. 2009; 51:872–877. DOI: 10.1111/j.1469-8749.2009.03269.x. PMID: 19416339.

9. Nishio Y, Koda M, Kamada T, Someya Y, Kadota R, Mannoji C, Miyashita T, Okada S, Okawa A, Moriya H, Yamazaki M. Granulocyte colony-stimulating factor attenuates neuronal death and promotes functional recovery after spinal cord injury in mice. J Neuropathol Exp Neurol. 2007; 66:724–731. DOI: 10.1097/nen.0b013e3181257176. PMID: 17882016.

10. Serefhanoglu S, Goker H, Buyukasik Y, Turgut M, Sayinalp N, Haznedaroglu IC, Aksu S, Akman U, Ozcebe OI. Changes in vascular endothelial growth factor, angio-poietins, and Tie-2 levels with G-CSF stimulation in healthy donors. Ann Hematol. 2009; 88:667–671. DOI: 10.1007/s00277-008-0657-7.

11. Haynes RL, Xu G, Folkerth RD, Trachtenberg FL, Volpe JJ, Kinney HC. Potential neuronal repair in cerebral white matter injury in the human neonate. Pediatr Res. 2011; 69:62–67. DOI: 10.1203/PDR.0b013e3181ff3792.

12. Fancy SP, Harrington EP, Yuen TJ, Silbereis JC, Zhao C, Baranzini SE, Bruce CC, Otero JJ, Huang EJ, Nusse R, Franklin RJ, Rowitch DH. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci. 2011; 14:1009–1016. DOI: 10.1038/nn.2855. PMID: 21706018. PMCID: 3145042.

13. O’Shea TM, Allred EN, Dammann O, Hirtz D, Kuban KC, Paneth N, Leviton A. ELGAN study Investigators. The ELGAN study of the brain and related disorders in extremely low gestational age newborns. Early Hum Dev. 2009; 85:719–725. DOI: 10.1016/j.earlhumdev.2009.08.060.

14. Najm FJ, Zaremba A, Caprariello AV, Nayak S, Freundt EC, Scacheri PC, Miller RH, Tesar PJ. Rapid and robust generation of functional oligodendrocyte progenitor cells from epiblast stem cells. Nat Methods. 2011; 8:957–962. DOI: 10.1038/nmeth.1712. PMID: 21946668. PMCID: 3400969.

15. Lee YH, Choi KV, Moon JH, Jun HJ, Kang HR, Oh SI, Kim HS, Um JS, Kim MJ, Choi YY, Lee YJ, Kim HJ, Lee JH, Son SM, Choi SJ, Oh W, Yang YS. Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy. J Transl Med. 2012; 10:58. DOI: 10.1186/1479-5876-10-58. PMID: 22443810. PMCID: 3369209.

16. Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M, Dinse HR, Dermietzel R, Jensen A. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res. 2006; 59:244–249. DOI: 10.1203/01.pdr.0000197309.08852.f5. PMID: 16439586.

17. García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005; 48:1416–1423. DOI: 10.1007/s10350-005-0052-6.

18. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363:1439–1441. DOI: 10.1016/S0140-6736(04)16104-7. PMID: 15121408.

19. Thomsen GM, Gowing G, Svendsen S, Svendsen CN. The past, present and future of stem cell clinical trials for ALS. Exp Neurol. 2014; 262(Pt B):127–137. DOI: 10.1016/j.expneurol.2014.02.021. PMID: 24613827.

20. Andressen C. Neural stem cells: from neurobiology to clinical applications. Curr Pharm Biotechnol. 2013; 14:20–28.

21. Purandare C, Shitole DG, Belle V, Kedari A, Bora N, Joshi M. Therapeutic potential of autologous stem cell transplantation for cerebral palsy. Case Rep Transplant. 2012; 2012:825289. PMID: 23259143. PMCID: 3505957.

22. Papadopoulos KI, Low SS, Aw TC, Chantarojanasiri T. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor Neurol Neurosci. 2010; 28:1–6.

23. Wang M, Yang Y, Yang D, Luo F, Liang W, Guo S, Xu J. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology. 2009; 126:220–232. DOI: 10.1111/j.1365-2567.2008.02891.x. PMCID: 2632684.

24. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997; 39:214–223. DOI: 10.1111/j.1469-8749.1997.tb07414.x. PMID: 9183258.

25. Palisano RJ, Cameron D, Rosenbaum PL, Walter SD, Russell D. Stability of the gross motor function classification system. Dev Med Child Neurol. 2006; 48:424–428. DOI: 10.1017/S0012162206000934. PMID: 16700931.

26. Shyu WC, Lin SZ, Lee CC, Liu DD, Li H. Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial. CMAJ. 2006; 174:927–933. DOI: 10.1503/cmaj.051322. PMID: 16517764. PMCID: 1405861.

27. Schäbitz WR, Krüger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J, Mier W, Kirsch F, Dittgen T, Bach A, Sommer C, Schneider A. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab. 2008; 28:29–43. DOI: 10.1038/sj.jcbfm.9600496.

28. Sevimli S, Diederich K, Strecker JK, Schilling M, Klocke R, Nikol S, Kirsch F, Schneider A, Schäbitz WR. Endogenous brain protection by granulocyte-colony stimulating factor after ischemic stroke. Exp Neurol. 2009; 217:328–335. DOI: 10.1016/j.expneurol.2009.03.018. PMID: 19332060.

29. Arien-Zakay H, Lecht S, Bercu MM, Tabakman R, Kohen R, Galski H, Nagler A, Lazarovici P. Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors. Exp Neurol. 2009; 216:83–94. DOI: 10.1016/j.expneurol.2008.11.006.

30. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007; 40:185–192. DOI: 10.1038/sj.bmt.1705722. PMID: 17563736.

31. Kuban JL, Hecht AB, Onderdonk T, Michael O’Shea N. Understanding the underlying beneficial biology of stem cells and the development and validation of more relevant animal models is required. Paneth Pediatr Res. 2010; 67:95–101.

32. Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R, Moore MA. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A. 1985; 82:1526–1530. DOI: 10.1073/pnas.82.5.1526. PMID: 3871951. PMCID: 397296.

33. Toth ZE, Leker RR, Shahar T, Pastorino S, Szalayova I, Asemenew B, Key S, Parmelee A, Mayer B, Nemeth K, Bratincsák A, Mezey E. The combination of granulocyte colony-stimulating factor and stem cell factor significantly increases the number of bone marrow-derived endothelial cells in brains of mice following cerebral ischemia. Blood. 2008; 111:5544–5552. DOI: 10.1182/blood-2007-10-119073. PMID: 18268092. PMCID: 2424152.

34. Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B. Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci U S A. 2003; 100:1364–1369. DOI: 10.1073/pnas.0336479100. PMID: 12538864. PMCID: 298778.

35. Wang L, Ji H, Zhou J, Xie J, Zhong Z, Li M, Bai W, Li N, Zhang Z, Wang X, Zhu D, Liu Y, Wu M. Therapeutic potential of umbilical cord mesenchymal stromal cells transplantation for cerebral palsy: a case report. Case Rep Transplant. 2013; 2013:146347. PMID: 23533920. PMCID: 3603664.

36. Sharma A, Gokulchandran N, Chopra G, Kulkarni P, Lohia M, Badhe P, Jacob VC. Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012; 21( Suppl 1):S79–S90. DOI: 10.3727/096368912X633798. PMID: 22507683.